Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
Summary
This investment underscores Zynext Ventures commitment to supporting disruptive healthcare innovations that address significant unmet medical needs.Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD. Recognizing the profound impact of sickle cell disease on patients lives, we are pleased to support Illexcor in their efforts to develop a novel therapeutic solution addressing this critical unmet medical need. Beyond the financial backing, Zynext Ventures will leverage its unique data analytics and strategic expertise to accelerate Illexcors path to delivering this potentially life-changing therapy globally. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars.